Euro RSCG Life LM&P Wins Pfizer Xalatan(R) Account

NEW YORK, March 21 /PRNewswire/ -- Euro RSCG Life, a leading healthcare communications network, announced that its LM&P division has won a significant piece of business in a competitive pitch conducted by Pfizer for its leading glaucoma therapy, Xalatan(R) (latanaprost ophthalmic solution).

Xalatan joins a portfolio of Pfizer products handled by LM&P including Chantix(TM) (varenicline); Genotropin(R) (somatropin {rDNA origin} for injection); Lyrica(R) (pregabalin); and maraviroc, a CCR5 Antagonist in development for treatment of HIV.

"We plan to fully deliver on the trust that has been placed in us," said David Paragamian, president of LM&P.

Xalatan is one of the leading products for Pfizer and is the #1 prescribed eye pressure-lowering medicine for people with high eye pressure or open-angle glaucoma.

About Euro RSCG Life

Euro RSCG Life aligns the company's 44 health-focused offices in 22 countries. It creates a single network with almost 1,000 employees that offers clients comprehensive communications disciplines, including advertising, public relations, event promotion, medical education, interactive marketing and consulting services. The network's client roster includes GlaxoSmithKline, Novartis, Pfizer, Sanofi-Aventis, Schering-Plough and Wyeth. Euro RSCG Life is part of Euro RSCG Worldwide, a leading integrated marketing communications agency that has been recognized as 2006 "Global Agency of the Year" by Advertising Age. Euro RSCG Worldwide is the largest unit of Havas, the world's fourth-largest communications group (Euronext Paris SA: HAV.Pa).